Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium‐glucose co‐transporter‐2 …
D Patoulias, C Papadopoulos… - The Journal of …, 2020 - Wiley Online Library
Type 2 diabetes mellitus (T2DM) constitutes a global pandemic, representing the 7th cause
of death worldwide. Morbidity and mortality of patients with T2DM are gradually increasing …
of death worldwide. Morbidity and mortality of patients with T2DM are gradually increasing …
[HTML][HTML] The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction …
EJM van Bommel, MHA Muskiet, MJB van Baar… - Kidney international, 2020 - Elsevier
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve hard renal outcomes in type 2
diabetes. This is possibly explained by the fact that SGLT2i normalize the measured …
diabetes. This is possibly explained by the fact that SGLT2i normalize the measured …
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
Cardiovascular and renal outcome trials (CVOTs) for glucagon-like-peptide-1 receptor
agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) highlight new …
agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) highlight new …
The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study
A Bechlioulis, G Markozannes, I Chionidi… - Journal of Diabetes and …, 2023 - Elsevier
Background Pulse wave velocity (PWV) and augmentation index (AIx) are indices used to
assess arterial stiffness. We aim to compare the effect of empagliflozin, liraglutide and their …
assess arterial stiffness. We aim to compare the effect of empagliflozin, liraglutide and their …
Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes
H Liu, VS Sridhar, D Montemayor… - Diabetes, Obesity …, 2021 - Wiley Online Library
Aim To examine the impact of the sodium‐glucose co‐transporter‐2 inhibitor, empagliflozin,
on plasma and urine metabolites in participants with type 1 diabetes. Material and Methods …
on plasma and urine metabolites in participants with type 1 diabetes. Material and Methods …
Interactive Effects of Empagliflozin and Hyperglycemia on Urinary Amino Acids in Individuals With Type 1 Diabetes
L Kugathasan, VS Sridhar, LE Lovblom, S Matta… - Diabetes, 2024 - Am Diabetes Assoc
Optimizing energy use in the kidney is critical for normal kidney function. Here, we
investigate the effect of hyperglycemia and sodium–glucose cotransporter 2 (SGLT2) …
investigate the effect of hyperglycemia and sodium–glucose cotransporter 2 (SGLT2) …
What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
VS Sridhar, HU Rahman… - Diabetes, Obesity and …, 2020 - Wiley Online Library
Over the past 5 years, sodium‐glucose cotransport 2 (SGLT2) inhibitors have been
increasingly regarded as glycaemic agents with cardiovascular (CV) and renal protective …
increasingly regarded as glycaemic agents with cardiovascular (CV) and renal protective …
[HTML][HTML] Cardiorenal protection in diabetic kidney disease
JF Lee, E Berzan, VS Sridhar… - Endocrinology and …, 2021 - synapse.koreamed.org
Over the last 5 years there have been many new developments in the management of
diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium …
diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium …
SGLT2 inhibition in type 1 diabetes with diabetic kidney disease: potential cardiorenal benefits can outweigh preventable risk of diabetic ketoacidosis
H Liu, VS Sridhar, BA Perkins, J Rosenstock… - Current Diabetes …, 2022 - Springer
Abstract Purpose of Review The aim of this review is to summarize existing research
investigating the use of sodium glucose cotransporter-2 (SGLT2) inhibitors in patients with …
investigating the use of sodium glucose cotransporter-2 (SGLT2) inhibitors in patients with …
Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results …
J Karalliedde, N Fountoulakis, D Stathi… - Frontiers in …, 2022 - frontiersin.org
Objective The mechanisms that explain the cardio-renal benefits of sodium glucose co-
transporter 2 (SGLT-2) inhibitors are unknown. The effect of SGLT-2 inhibitors on arterial …
transporter 2 (SGLT-2) inhibitors are unknown. The effect of SGLT-2 inhibitors on arterial …